Analysis

As Featured In

Bespoke Sector Analysis

June 5, 2020
Evolution Briefing: Lonza announce new CEO
May 6, 2020
Moderna and Lonza Announce Worldwide Collaboration to Manufacture vaccine against COVID-19
February 4, 2019
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
October 10, 2018
Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX
Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX
August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
July 12, 2018
Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2
Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2
April 12, 2018
Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
March 27, 2018
All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation
March 8, 2018
Charles River Laboratories M&A Activity Analysis: a Differentiated Strategy Delivering Results
Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results
February 22, 2018
Making Large-Scale Biomanufacturing More Efficient and Affordable: Have Novo Nordisk Foundation Made a Major Breakthrough?
Making Large-Scale Biomanufacturing More Efficient and Affordable: Have Novo Nordisk Foundation Made a Major Breakthrough?
February 20, 2018
2018 Global Drug Development IPO Review
2018 Global Drug Development IPO Analysis: $10.24B Raised in Strongest Year on Record



Contact Us